934584-88-0

Basic information

• Product Name: 1-(1,1-dimethylethyl) 2-methyl (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate
• Synonyms: 1-(1,1-dimethylethyl) 2-methyl (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate
• CAS NO: 934584-88-0
• Molecular Formula: C₂₄H₂₈FNO₅
• Molecular Weight: 429.4812232
• Mol File: 934584-88-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(1,1-dimethylethyl) 2-methyl (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1,1-dimethylethyl) 2-methyl (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate(934584-88-0)
• EPA Substance Registry System: 1-(1,1-dimethylethyl) 2-methyl (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate(934584-88-0)

Safety Data

• Hazardous Substances Data: 934584-88-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tadalafil is used as a medication for the treatment of erectile dysfunction and benign prostatic hyperplasia. It functions by enhancing blood flow to the genital area, which aids in achieving and maintaining an erection. The increased blood flow also helps alleviate the symptoms of an enlarged prostate, improving urinary flow and reducing the frequency of urination.
Used in Research and Development:
In addition to its clinical applications, tadalafil is utilized in research and development for studying the mechanisms of PDE5 inhibition and its potential implications in various medical conditions. This research can lead to the discovery of new therapeutic approaches and the development of novel medications with similar or improved properties.

Upstream product

• 345-35-7 2-fluorobenzyl chloride 
• 934584-66-4 1-(tert-butyl) 2-methyl (2S,5R)-5-(4-(benzyloxy)phenyl)pyrrolidine-1,2-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 120186-59-6 (4-(benzyloxy)phenyl)magnesium bromide 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 6793-92-6 p-benzyloxyphenylbromide 
• 446-48-0 o-fluorobenzyl bromide 
• 934240-62-7 (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate 

Downstream Products

• 934240-62-7 (2S,5R)-methyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxylate 
• 934240-30-9 (2S,5R)-5-(4-((2-fIuorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide 
• 934240-31-0 (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide monohydrochloride 
• 934240-45-6 tert-butyl (2S,5R)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)-phenyl)pyrrolidine-1-carboxylate 
• 934584-98-2 1-(1,1-dimethylethyl) 2-methyl (2R,5R)-2-[(2Z)-4-bromo-2-buten-1-yl]-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate 
• 934584-83-5 1-(1,1-dimethylethyl) 2-methyl (2R,5R)-2-(cyanomethyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate 
• 934584-89-1 1-(1,1-dimethylethyl) 2-methyl (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(2-propen-1-yl)-1,2-pyrrolidinedicarboxylate 

Relevant articles and documents

Synthesis of Vixotrigine, a Use-Dependent Sodium Channel Blocker. Part 1: Development of Bulk Supply Routes to Enable Proof of Concept

Two syntheses of vixotrigine are reported. Route 1, adapted from the medicinal chemistry route, enabled rapid delivery of drug substance for clinical development. Route 2, which was developed to address many of the limitations of Route 1, was used to manu

Synthesis of Vixotrigine, a Voltage- And Use-Dependent Sodium Channel Blocker. Part 2: Development of a Late-Stage Process

As vixotrigine (1) entered a later clinical phase for trigeminal neuralgia (Zakrzewska, J. M.; et al. Lancet Neurol. 2017, 16, 291-300), the development of a sustainable late-stage process was required to meet the supply needs for formulation optimization

PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYROLIDINE DERIVATIVES

The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for pr

PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES

The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for pr

PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)

The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVE AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS

The invention relates to quaternary E-aminocarboxyamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, X, q and n are as defined in claim 1, for treating diseases and conditions mediated by modulation of voltage-gated sodium channels.